natgillin/translations-raw huggingface dataset:
A pharmaceutical composition according to claim 1, which further comprises an excipient selected from the group consisting of disintegrants, lubricants, plastizicers, and fillers. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži pomoćnu tvar, koja se bira iz skupine koju čine sredstva za raspadanje, maziva, plastifikatori, te punila.
a nucleoside reverse transcriptase inhibitor; wherein TMC278 and the nucleoside reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily. 
inhibitor nukleozidne reverzne transkriptaze; pri čemu su TMC278 i inhibitor nukleozidne reverzne transkriptaze terapeutski učinkoviti inhibitori HIV-a u dozi koja se može davati jednom dnevno.
A compound of claim 6 having the Formula B1, selected from compounds 9-16 of Table 2: 
Spoj prema patentnom zahtjevu 4 koji ima formulu B,, izabran od spojeva 9-16 iz Tabele 2:
A process according to claim 26, wherein the compound of formula (1), or tautomer, or salt thereof, has a configuration according to formulae (1-a), or tautomer thereof, wherein in above formulae R1 is hydrogen or a nitrogen protecting group. 
Postupak prema zahtjevu 69 ili 72, naznačen time, da spoj formule (1) ili njegova sol, ima konfiguraciju u skladu sa sljedećom formulom (1-a): pri čemu u gornjoj formuli, R1 je vodikova ili dušikova zaštitna skupina.
The method of clause 25, wherein the diagnostic test is microscopic observation of the morphology of the cell. 
VILI, pri čemu dijagnostičko ispitivanje je mikroskopsko promatranje morfologije odvojene cirkulirajuće stanice tumora.
The process for the preparation of Iopamidol or Iomeprol by starting from the corresponding compound of formula (2) prepared according to the process of any one of claims 1-10. 
Postupak za pripremanje lopamidola ili Ilomeprola polazeći od odgovarajućeg spoja formule (2) dobivenog prema postupku prema bilo kojem od zahtjeva 1-10.
The method of clause 42, wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Farmaceutska kompozicija prema patentnom zahtjevu 6, naznačena time što su kognitivni poremećaji i bolesti izabrani iz grupe koju čine Alzheimer-ova bolest, oblici gubitka pamćenja i gubitak pamćenja povezan sa starošću.
A compound of the invention in free or salt form and, where possible, in pharmaceutically acceptable acid addition salt form for use as a vanilloid receptor blocker, e.g., for use in any of the particular indications set forth hereinabove; 
(1) spoj formule (21) ili (Ia) u slobodnom obliku ili u obliku soli 1, gdje je to moguće, u obliku farmaceutski prihvatljive kiselinske adicijske soli za upotrebu kao blokera vaniloid receptora, npr. za upotrebu kod bilo koje od posebnih gore navedenih indikacija;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
The hole (31) of the adapter body is suitably dimensioned to receive the head (25) of the adjusting screw/bolt. Since the head (25) of the adjusting screw has a polygonal, preferably hexagonal section, the hole (31) of the adapter body has a polygonal, preferably hexagonal section. 
Kontrolni sustav (1) prema zahtjevu 4, naznačen time da vrh (25) spomenutog prilagodljivog vijka ima šesterokutni dio i spomenuti otvor (31) trupa adaptera ima šesterokutni presjek komplementaran s obodom prilagodljivog vijka.
The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 5, wherein R3 is a hydrogen atom or a methyl group. 
Spoj ili njegova farmaceutski prihvatljiva kisela adicijska sol prema zahtjevu 5, pri čemu R, je vodikov atom 1li metilna skupina.
The container of claim 6, wherein the salt is the Bform of the DL-lactic acid addition salt. 
Sol u skladu s patentnim zahtjevom 13, pri čemu je navedena sol dodatna sol DL-mliječne kiseline.
Discussion of pharmacological results 
Rasprava o farmakološkim rezultatima
The composition of claim 13, wherein the one or more additional therapeutics is selected from the group consisting of: an anti-PD1 antibody, an anti-LAG3 antibody, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, and combinations thereof. 
Antitijelo za primjenu u metodi iz patentnog zahtjeva 18, gdje je dodatni terapeutik anti-PD1 antitijelo, anti-LAG-3 antitijelo, anti-CTLA-4 antitijelo, ili anti-PD-L1 antitijelo.
In some embodiments, the pharmaceutical composition is formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion. 
Farmaceutski pripravak prema zahtjevu 9, naznačen time da je farmaceutski pripravak formuliran za davanje: oralno, = intraadipozno, = intraarterijski, = intraartikularno, = intrakranijalno, = intradermalno, = intralezionalno, intramuskularno, intranazalno, intraokularno, intraperikardijalno, intraperitonealno, intrapleuralno, intraprostatski, intrarektalno, intratekalno, intratrahealno, intratumoralno, intraumbilikalno, intravaginalno, intravenozno, intravezikularno, intravitrealno, liposomalno, lokalno, mukozalno, parenteralno, rektalno, subkonjunktivno, subkutano, sublingvalno, topikalno, transbukalno, transdermalno, vaginalno, u kremi, u lipidnim pripravcima, putem katetera, putem ispiranja, kontinuiranom infuzijom, infuzijom, inhalacijom, putem injekcije, putem lokalne isporuke, ili putem lokalizirane perfuzije.
The secondary station of claim 10, wherein the second plurality of resource sets comprise a plurality of component carriers, the control channel search spaces being distributed over the component carriers, and wherein the secondary station determines from a presence of the control channel on a specific component carrier the indication of the particular resource set within which the allocated resource is located. 
Metoda iz patentnog zahtjeva 1 ili 2, gdje veliki broj skupova resursa sadrži veliki broj nositelja komponenti, prostore za pretragu kontrolnog kanala koji su distribuirani preko nositelja komponenti, i gdje sekundarna stanica (110) određuje iz mapiranja 1 prisustva kontrolnog kanala na specifičnom nositelju komponente indikaciju skupa resursa unutar kojeg je smješten alocirani resurs.
The residue is taken up in 250 ml isopropyl acetate and stirred 2 hours at RT. 
Ostatak se preuzme u 250 ml izopropil acetata i miješa tijekom dva sata na RT.
Process according to claim 8, characterized in that the amount of calcium in the liquid pharmaceutical formulation to be administered to the patient is less than 50 ppm and in that the amount of calcium in the ingredients used for the pharmaceutical solution in step b), namely the DOTA powder, water and meglumine, is less than 20 ppm, advantageously less than 15 ppm. 
PPI i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu, odnosno u kelatnom prahu, naročito DOTA, vodi i megluminu, manja od 50 ppm, poželjno manja od 20 ppm.
Particularly where a tumour over-expresses EGFR. 
Pogotovo kod tumorske ekspresije EGFR.
The method of claim 1, wherein the target DNA is inside of a cell and the method comprises introducing into the cell the single molecule DNA-targeting RNA or a nucleic acid that encodes the single molecule DNA-targeting RNA. 
RNK jednostruke molekule koja cilja na DNK, ili DNK-polinukleotid koji kodira navedenu RNK koja cilja na DNK, dok navedena RNK jednostruke molekule koja cilja na DNK, obuhvaća sljedeće:
The solvent composition of claim 9, wherein the solvent composition comprises between about 20.0 wt.% to about 40.0 wt.% additional solvent. The solvent composition of claim 9, wherein the solvent composition comprises between about 4.0 wt.% to about 12.0 wt.% cationic surfactant. The solvent composition of claim 9, wherein the solvent composition comprises between about 1 wt% to about 99 wt % diluent. 
Formulacija otapala prema patentnom zahtjevu 8, naznačen time, što formulacija otapala sadrži od oko 20,0 % masenog udjela do oko 40,0 % masenog udjela dodatnog otapala, opcionalno naznačena time što dodatno otapalo sadrži dipropilen-glikol. Formulacija otapala prema patentnom zahtjevu 8, naznačena time, što formulacija otapala sadrži od oko 4,0 % masenog udjela do oko 12,0 % masenog udjela kationskog surfaktanta, opcionalno naznačena time, što kationski surfaktant sadrži kvaternarnu sol amonijaka.
The compound of claim 17, wherein Rd is cyclopropyl. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski pripravak, naznačen time, da sadrži spoj sukladno bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljivi nosač ili otapalo.
A process according to claim 18, wherein pressure is applied to the peripheral flange at a pressure of from 206.84KPa to 1,241.06KPa (30 psi to 180 psi) for a period of time of from 0.5 seconds to 5 seconds, preferably 758.42KPa (110 psi) for 1 second. 
Postupak prema Zahtjevu 18, gdje se na prirubnicu izvedenu duž oboda djeluje tlakom od 206,84 kPa do 1.241,06 kPa (30 psi do 180 psi) tijekom perioda vremena od 0,5 s do 5 s, a poželjno 758,42 kPa (110 psi) tijekom perioda od 1 sekunde.
The polypeptide of any one of items 1-8, wherein the polypeptide comprises an amino acid sequence according to SEQ ID NO:32 or SEQ ID NO: 66. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-9, gdje polipeptid sadrži aminokiselinsku sekvencu u skladu sa SEK ID BR:32 ostaci 1-567 ili SEK ID BR:66 ostaci 1-3758.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
A kit of parts comprising at least one balloon (31 to 35) of elastomeric material, a pack of sheet material (11 to 14) and at least one patch (21 to 25) carried as a peelable patch on one surface of the pack, the or each patch having its peelable surface provided with adhesive means and having an opening in a generally central region so that it may be removed from the pack and affixed to the balloon after inflation so as to prevent propagation of a tear caused by the balloon being punctured at a location within the opening defined by the patch by a pin or other sharp object. 
HR P20160487 T1 PATENTNI ZAHTJEVI Komplet dijelova koji sadrži najmanje jedan balon (31 do 35) od elastomernog materijala, paket od plošnog materijala (11 do 14) i najmanje jednu zakrpu (21 do 25) koja se na jednoj površini paketa izvodi kao odljepljiva zakrpa, ili svaka zakrpa ima svoju odljepljivu površinu predviđenu s ljepljivim sredstvima i ima otvor u uglavnom središnjem području tako da se može ukloniti iz pakiranja 1 pričvrstiti na balon nakon napuhavanja tako da se spriječi širenje kidanja izazvano time da je balon probušen pomoću klina ili drugog oštrog objekta na mjestu unutar otvora koji je definirano zakrpom.
A composition suitable for leather tanning and obtained by the method of any one of the claims 1-3 in a form of a powdery solid having moisture content less than 20 % by weight comprising zeolite having a Si to Al ratio from 0.7 to 2.5 treated with concentrated monocarboxylic acid selected from the group of formic acid, acetic acid, propionic acid, glycolic acid, lactic acid and mixtures thereof, the concentration of said monocarboxylic acid being more than 84% by weight, and having the zeolite structure intact. 
Pripravak prikladan za štavljenje kože i dobiven postupkom prema bilo kojem od zahtjeva 1-3 u obliku praškaste obrađen koncentriranom monokarboksilnom kiselinom izabranom iz grupe koju čine mravlja kiselina, octena kiselina, propionska kiselina, glikolna kiselina, mliječna kiselma i njihove smjese, koncentracija te monokarboksilne kiseline veća je od 84% težinski, i struktura zeolita je intaktna.
The present invention relates to a compound of formula I: 
PATENTNI ZAHTJEVI 1. Spoj formule I: idu
A compound represented by the formula (5): wherein R is a fluorine atom or a methoxy group, and R100 is a C1 - C4 alkyl group. 
Spoj, naznačen time što je prikazan formulom (5): [image], gdje je R atom fluora ili skupina metoksi, a R100 je C1-C4 alkilna skupina.
A method for manufacturing a residential compartment (2) for a fish farming plant (1) comprised of polyethylene modules according to claim 2, comprising plastic welding the individual modules to each other in an end-to-end relation until an elongate oval residential compartment (30) including a number of modules as determined by the desired capacity for the fish farming plant (1) has been formed. 
Postupak za proizvodnju stambenog odjeljka (2) za postrojenje za uzgoj ribe (1) sastavljeno od polietilenskih modula prema zahtjevu 2, naznačen time da obuhvaća međusobno plastično zavarivanje pojedinačnih modula u odnosu od kraja do kraja sve do oblikovanja produljenog izduženog ovalnog stambenog odjeljka (30) koji uključuje veći broj modula koji su određeni željenim kapacitetom postrojenja za uzgoj Tibe (1).
An elongate body for needle-free parenteral injection at low velocity from a device, the body having at least one pointed end and comprising at least one active material, characterised in that the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°, and wherein the body is a solid vaccine formulation which is at least partly crystalline, said body comprising one or more antigenic or immunogenic agents and optionally one or more adjuvants. 
Izduženo tijelo za parenteralno ubrizgavanje bez igle pri maloj brzini 1z uređaja, pri čemu tijelo koje ima najmanje jedan šiljati kraj i sadrži najmanje jedan aktivni materijal, naznačeno time što, to tijelo ima tlačnu čvrstoću veću od ili jednak 5 Newtona i šiljasti kraj ima kut između oko 10-50", i gdje je tijelo formulacija cjepiva u krutom obliku koje je barem djelomično kristalično navedeno tijelo sadrži jedan ili više antigenih ili imunogenih sredstava i po izboru jedan ili više pomoćnih sredstava.
The system of claim 1 wherein the nozzle provides substantially uniform consistent spray but not atomization of the mixture. 
Sustav prema zahtjevu 1, naznačen time što mlaznica osigurava u biti ravnomjeran konzistentan mlaz ali ne i usitnjavanje mješavine.
Phencyclidine hydrochloride (PCP, Sigma, UK) was dissolved in distilled water. 
Fenciklidin hidroklorid (PCP, Sigma, UK) je bio otopljen u destiliranoj vodi.
In further embodiments of the processes according to the invention, the employed pieces of wood are glued having very high wood humidity (wet), whereby, for example, said high wood humidity can also be achieved by watering said pieces of wood. 
U daljnjem ostvarenju postupka koji je u skladu s ovim izumom korišteni komadi od drva se lijepe tako da imaju vrlo visoku vlažnost drva (mokri su), pri čemu se, na primjer, navedena visoka vlažnost drva može također dobiti potapanjem u vodu navedenog komada drva.
A process according to claim 10 wherein the industrial process is a metal finishing process, a metal etching process, a metal extraction process, a mineral processing process, a coal seam gas extraction process, a shale gas extraction process or a shale oil extraction process. 
Postupak prema zahtjevu 10 naznačen time što industrijski postupak je postupak završne obrade metala, postupak metalnog jetkanja, postupak ekstrakcije metala, proces prerade minerala, proces ekstrakcije plina iz ugljena, postupak ekstrakcije plina iz škriljca ili postupak ekstrakcije nafte iz škriljca.
Although the inclusion of a communications means is not necessary in the performance of the energy savings device and system 1, it is a feature that permits easier use of the device and system 1 . 
Sustav za uštedu energije iz zahtjeva 1, gdje uređaj za uštedu energije nije izveden tako da nadzire karakteristike napona na koji je spojen.
Also, the container 101 may include a plurality of ridges 102 provided on the outer surface of the container 101. 
Također, posuda 101 može uključivati niz raznih izbočenja 102 koji se nalaze na vanjskoj površini posude 101.
In a third aspect, this invention is therapeutic methods, particularly in a human, of one or more of: potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow, by the administration of compounds of the first aspect of this invention or a pharmaceutical composition of the second aspect of this invention, and the use of the compounds of the first aspects of this invention in the manufacture of a medicament for one or more of the therapeutic methods mentioned above. 
U trećem aspektu, ovaj izum su terapeutske metode, naročito za čovjeka, jedna ili više od: pojačavanja citotoksičnog efekta kemoterapeutskih agensa u stanicama tumora, pokazivanja selektivnog citotoksiciteta u stanicama tumora, podizanja produkcije GM progenitora u koštanoj srži, stimuliranja diferencijacije stanica koštane srži, ublažavanja mielosupresivnog efekta kemoterapijskih agensa i moduliranja hematopoiesisa u koštanoj srži, davanjem spojeva iz prvog aspekta ovog izuma ili farmaceutskih pripravaka iz drugog aspekta izuma, i upotrebom spojeva iz prvog aspekta izuma za proizvodnju lijeka za jednu ili više od: pojačavanja citotoksičnog efekta kemoterapeutskih agensa u stanicama tumora, pokazivanja selektivnog citotoksiciteta u stanicama tumora, podizanja produkcije GM progenitora u koštanoj srži, stimuliranja diferencijacije stanica koštane srži, ublažavanja mielosupresivnog efekta kemoterapijskih agensa i moduliranja hematopoiesisa u koštanoj srži.
It is an object of this invention to provide stable formulations of ecteinascidins, and methods of making such formulations. 
Cilj ovog izuma je osigurati stabilne oblike ekteinascidina, i postupke za pripremu takvih oblika.
The compound for use according to claim 16, wherein said second active agent is selected from the group consisting of a DNA-hypomethylating agent, a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a cytokine, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an anti-thymocyte globulin, an immunosuppressive agent, and a corticosteroid or a pharmacological derivative thereof or wherein said second active agent is an anti-PDl antibody or an anti-PDL1 antibody. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je drugo aktivno sredstvo izabrano iz skupine koja se sastoji kemoterapeutskog sredstva, DNA-hipometilirajućeg sredstva, terapeutskog antitijela koje se specifično veže na antigen raka, hematopoetski faktor rasta, citokin, antibiotik, inhibitor cox-2, imunomodulatorni agens, antimocitni globulin, imunosupresivno sredstvo i kortikosteroid ili farmakološki derivat ili gdje je drugo aktivno sredstvo anti-PD1 antitijelo ili anti-PDL1 antitijelo.
Certain specific embodiments provided herein describe a compound of formula (I-L): 
Spoj sukladno patentnom zahtjevu 5, formule (I-L): ž a šo
a stuffed casing rotating unit for rotating the stuffed casing having the adhesive applied thereto; and 
jedinicu za rotiranje koja rotira ispunjeni ovitak na koji je nanesen ljepljivi materijal;
A pharmaceutical composition according to any one of paras. 1 to 13, wherein said arginine, if present, is: free L-arginine or a pharmaceutically acceptable salt of L-arginine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni L-arginin ili farmaceutski prihvatljiva sol od L-arginina.
The polymorph according to any one of clauses 8-9, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 3.9 +/- 0.3 degrees, about 17.5 +/- 0.3 degrees, and about 22.0 +/- 0.3 degrees 2-theta. 
Polimorf prema bilo kojem od zahtjeva 8-9, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima karakteristične vrškove izražene u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
A coextrusion die, comprising a layer sequence repeater module as claimed in any of claims 1 to 16. The coextrusion die of Claim 19, comprising at least two of the layer sequence repeater modules. The coextrusion die of Claim 19, comprising at least three of the layer sequence repeater modules. 
Kalup za suekstrudiranje, naznačen time što sadrži modul za ponavljanje niza slojeva u skladu s bilo kojim od patentnih zahtjeva 1 do 16. Kalup za suekstrudiranje u skladu s patentnim zahtjevom 19, naznačen time što sadrži najmanje dva modula za ponavljanje niza slojeva.
The crystalline form of Febuxostat, designated Form F2, according to claim 6, further characterized by additional X-ray powder diffraction peaks at: 13.1 °, 14.7°, 17.5°, 24.4° and 25.2° ± 0.2° 2θ. 
Kristalni oblik febuksostata, označen kao Oblik F2, u skladu s patentnim zahljevom 6, naznačen time što je za njega dodatno karakteristična dodatna difrakcija rendgenskih zraka na prahu sa signalima na: 13,1 %, 14,7%, 17,5",
A composition derived from the corn plant, or parts thereof, as set forth in claim 1 or 2, wherein said composition comprises a detectable amount of a DNA molecule encoding Cry2Ab and Cry1A.105 and DNA having the nucleotide sequences of SEQ ID NOs: 1 and 2 as defined in claims 1 or 2, and wherein said composition is a commodity product selected from corn meal, corn oil, corn cake, corn seed, corn germ, corn starch, corn flour, corn pollen, corn silk, corn steep liquor, corn malt, corn sugar, corn syrup, margarine produced from corn oil, distillers dry goods solids (DDGS), cosmetic and bulking agent. 
Pripravak izveden iz biljke kukuruza ili dijelova iste, kao što je navedeno u zahtjevu 1 ili 2, pri čemu spomenuti pripravak sadrži prepoznatljivu količinu DNA molekula koje kodiraju Cry2Ab i Cry1A.105 1 čije DNA nukleotidne sekvence imaju SEQ ID NO:1 12, kao što je definirano u zahtjevima 1 ili 2, pri čemu je spomenuti pripravak robni proizvod odabran iz kukuruznog brašna, kukuruznog ulja, kukuruznih kolača, sjemena kukuruza, klica kukuruza, kukuruznog škroba, kukuruzne peludi, kukuruzne svile, tekućine od namakanja kukuruza, kukuruzne sladi, kukuruznog šećera, kukuruznog sirupa, margarina proizvedenog od kukuruznog ulja, sušenih krutih tvari, kozmetičkih sredstava i sredstava za bubrenje. Postupak za proizvodnju biljke kukuruza otporne na insekte, obuhvaća:
providing a portion of the tissue-engineered product containing cells and a proportional amount of the cell culture conditioned medium; 
(a) pripreme dijela produkta preinačenog-tkiva koji sadržava stanice i proporcionalnu količinu kondicioniranog medija stanične kulture;
The compound or therapeutically acceptable salt thereof of claim 1, wherein the compound is chosen from a group consisting of: 
Spoj ili terapeutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da je spoj odabran iz skupine koju čine: